ECM
ALBO

Endurant Capital Management’s Albireo Pharma Inc ALBO Stock Holding History

Endurant Capital Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-217,209
Closed -$4.69M – 68
2022
Q4 		$4.69M Buy
217,209
+44,588
+26% +$942K 1.91% 14
2022
Q3 		$3.34M Buy
172,621
+134,786
+356% +$2.79M 1.09% 26
2022
Q2 		$751K Sell
37,835
-82,999
-69% -$2.19M 0.26% 42
2022
Q1 		$3.6M Buy
120,834
+55,196
+84% +$1.62M 0.95% 29
2021
Q4 		$1.53M Sell
65,638
-51,690
-44% -$1.37M 0.37% 49
2021
Q3 		$3.66M Buy
117,328
+13,816
+13% +$427K 0.83% 30
2021
Q2 		$3.64M Buy
103,512
+337
+0.3% +$11K 1% 38
2021
Q1 		$3.64M Buy
103,175
+60,883
+144% +$2.25M 0.95% 38
2020
Q4 		$1.59M Sell
42,292
-9,839
-19% -$358K 0.57% 44
2020
Q3 		$1.74M Buy
+52,131
New +$1.52M 0.51% 49

Other funds holding ALBO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Endurant Capital Management's ALBO Position: Q1 2023 in Review

Endurant Capital Management sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 217,209 shares — an estimated $4.69M sold.

Endurant Capital Management first reported a position in ALBO in Q3 2020 and held it in 10 quarters. The position peaked at $4.69M in Q4 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Endurant Capital Management reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Endurant Capital Management sold 217,209 Albireo Pharma Inc shares in Q1 2023, an estimated $4.69M.
  • Endurant Capital Management first reported a position in Albireo Pharma Inc in Q3 2020 and held it in 10 quarters.
  • Endurant Capital Management's Albireo Pharma Inc position peaked at $4.69M in Q4 2022.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.